Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers

Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms

(2015) Vincenza Cifarelli et al.   DIABETES

Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma

(2015) Brian M. Slomovitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

(2013) Helen J. Mackay et al.   CANCER

Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

(2011) Irina N. Alimova et al.   CELL CYCLE

Mechanisms of mTOR inhibitor resistance in cancer therapy

(2011) Jennifer S. Carew et al.   Targeted Oncology

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells

(2010) Mahvash Zakikhani et al.   BREAST CANCER RESEARCH AND TREATMENT

Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer

(2010) E. Rozengurt et al.   CLINICAL CANCER RESEARCH

A phase I study of temsirolimus and metformin in advanced solid tumours

(2010) Mary J. MacKenzie et al.   INVESTIGATIONAL NEW DRUGS

Metformin Disrupts Crosstalk between G Protein-Coupled Receptor and Insulin Receptor Signaling Systems and Inhibits Pancreatic Cancer Growth

(2009) K. Kisfalvi et al.   CANCER RESEARCH

Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer

(2009) Sao Jiralerspong et al.   JOURNAL OF CLINICAL ONCOLOGY